Is Johnson&Johnson (JNJ) stock a buy or sell?
Johnson & Johnson has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings. According to analysts' consensus price target of $189.75, Johnson & Johnson has a forecasted upside of 15.5% from its current price of $164.34.
Why did Johnson&Johnson stock fall 6% in October 2019?
JNJ stock fell more than 6% on a single day in October 2019 after an FDA test found trace amounts of asbestos in a single bottle of baby powder purchased online. J&J later said an investigation showed no asbestos in additional samples from that bottle and lot.
Is JNJ stock flirting with its buy point?
For the year, JNJ stock analysts call for adjusted profit of $9.82 per share on $94.45 billion in sales, up a respective 22% and 14%. JNJ stock is forming a cup-with-handle base with a buy point at 173.61, according to MarketSmith.com. The stock is now flirting with its buy point.
What is the upside for Johnson&Johnson's stock?
On average, they anticipate Johnson & Johnson's stock price to reach $152.10 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
Is JNJ a good buy right now?
The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Is JNJ a good long term investment?
Johnson & Johnson Stock: What You Need To Know Johnson & Johnson stock (NYSE: JNJ) is one of the best-performing stocks on the Dow Jones Industrial Average, gaining more than 20% in the past 12 months. In large part, this is due to the company's impressive performance in the medical device segment.
What is the future of JNJ stock?
Stock Price Forecast The 16 analysts offering 12-month price forecasts for Johnson & Johnson have a median target of 187.00, with a high estimate of 215.00 and a low estimate of 173.00. The median estimate represents a +4.32% increase from the last price of 179.26.
Why is JNJ a good stock to buy?
Johnson & Johnson (NYSE:JNJ) is an ideal investment choice for risk-averse market participants, looking toward growth and profitability. JNJ's strong financial fundamentals and its market position make it a highly secure option, with its diversified segments that result in a minimized risk exposure for the company.
Is JNJ undervalued?
The company's cash flows seem to be undervalued, and investors might be able to take advantage of the recent market pessimism. So while earnings quality is important, it's equally important to consider the risks facing Johnson & Johnson at this point in time.
Is Johnson and Johnson a good company?
Johnson & Johnson is the world's largest health care company. It is also the highest paid drug company in the world. J&J remains at the top of the Big Pharma list of powerful corporations with more than $82 billion in annual revenue in 2020. Its top products include Tylenol, Stelara, Invega and various medical devices.
When was the last time JNJ stock split?
1996The last stock split announced by Johnson & Johnson was in 1996, when shares were split 2-for-1. On April 17, Johnson & Johnson announced sales and earnings for the first quarter of 2001. Sales of $7.8 billion and net earnings of $1.5 billion increased by 6.5% and 14.2%, respectively, over first-quarter 2000 results.
Does Johnson and Johnson have any subsidiaries?
Johnson & Johnson Vision Care, Inc. JOM Pharmaceutical Services, Inc. LifeScan, Inc. McNeil Consumer Pharmaceuticals Co.
Why is Johnson and Johnson so big?
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. It comprises some 250 subsidiaries, which clearly means that the business is extremely well diversified.
Is Costco a good stock to buy?
Oppenheimer analyst Rupesh Parikh believes that Costco remains a great investment and that the discount in the stock is a great opportunity to buy it at a lower price. In a recent report, the analyst highlighted Costco's strong management team and good track record of shareholder returns.
What are Johnson and Johnson products?
Where is Johnson and Johnson located?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands ; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
The healthcare giant is reportedly under investigation by the Department of Justice
Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey. Read More.
What happened
Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007. Follow @BiologyFool
So what
Shares of Johnson & Johnson ( NYSE:JNJ) closed down 4.15% on Friday after Bloomberg reported that the U.S. Department of Justice (DOJ) is investigating the healthcare conglomerate as to whether the company lied about possible cancer risks from its talcum powder.
Now what
Bloomberg cited unnamed sources, but it seems likely that the report of the investigation is real -- unlike press reports of potential mergers by unnamed sources, which only sometimes come to fruition.
What are Johnson and Johnson products?
Johnson & Johnson is scheduled to release second-quarter earnings on Tuesday, but it seems likely the company won't comment on the investigation other than to say it's cooperating with officials.
Where is Johnson and Johnson located?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands ; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women’s health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
What happened
Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
So what
Shares of Johnson & Johnson (NYSE: JNJ) closed down 4.15% on Friday after Bloomberg reported that the U.S. Department of Justice (DOJ) is investigating the healthcare conglomerate as to whether the company lied about possible cancer risks from its talcum powder.
Now what
Bloomberg cited unnamed sources, but it seems likely that the report of the investigation is real -- unlike press reports of potential mergers by unnamed sources, which only sometimes come to fruition.
How much did J&J pay for the opioid crisis?
Johnson & Johnson is scheduled to release second-quarter earnings on Tuesday, but it seems likely the company won't comment on the investigation other than to say it's cooperating with officials.
How much did J&J settle with Ohio?
J&J will pay $5 billion to settle lawsuits claiming the company had a part in the nation's opioid epidemic. Drug distributors McKesson, AmerisourceBergen and Cardinal Health will pay a combined $21 billion. According to reports, some 40 states could sign onto the deal.
How much did Johnson and Johnson pay for the opioids?
J&J also settled with two Ohio counties for $10 million. In addition, Johnson & Johnson will pay $5 million in legal fees and make $5.4 million in charitable giving, for a total payout of $20.4 million.
Why is J&J paused?
More bullishly, Johnson & Johnson nabbed a $5 billion deal to settle thousands of lawsuits related to its production of opioids. Related to that, drug distributors McKesson ( MCK ), AmerisourceBergen ( ABC) and Cardinal Health ( CAH) will pay a combined $21 billion.
Do J&J need a second shot?
That followed regulators' decision earlier this year to temporarily pause use of the J&J injection following separate reports of blood clots in women.
Is Ashtyn Evans bullish on Johnson and Johnson?
The authors suggested J&J vaccine recipients would need to receive a second shot of one of the messenger RNA vaccin es from Pfizer ( PFE) or Moderna ( MRNA ). Also this month, the FDA added a warning to the label for J&J's shot regarding the potential for Guillain-Barre syndrome.
Does J&J have a delta shot?
Edward Jones analyst Ashtyn Evans is bullish on Johnson & Johnson's chances. "The company's earnings growth has accelerated, driven by newly launched drugs and a decreasing impact from patent losses," she said in a post-earnings report to clients.
Ownership
- Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol \"JNJ.\" Johnson & Johnson's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.04%), Northern Trust Corp (1.30%), Boston Partners (0.46%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Swiss National Bank (0.37%) an…
Release
- Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July 16th 2019. View Earnings Estimates for Johnson & Johnson.
Sales
- Johnson & Johnson issued an update on its FY19 earnings guidance on Tuesday, April, 16th. The company provided earnings per share (EPS) guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.59. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue estimate of $81.17 …
Risks
- 11 brokerages have issued 1-year price targets for Johnson & Johnson's shares. Their forecasts range from $129.00 to $157.00. On average, they expect Johnson & Johnson's share price to reach $146.00 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
Ratings
- 11 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Johnson & Johnson in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Johnson & Johnson.
Reviews
- News headlines about JNJ stock have been trending positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Johnson & Johnson ea…
Business
- Johnson & Johnson has a market capitalization of $368.09 billion and generates $81.58 billion in revenue each year. The company earns $15.30 billion in net income (profit) each year or $8.18 on an earnings per share basis. Johnson & Johnson employs 135,100 workers across the globe.